secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001493152-23-009856
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce reports FY2022 net loss $24.2M, cash $3.1M; $3M equity raise; clinical milestones achieved
--------------------------------------------------------------------------------

- Q4 net loss $5.5M ($10.0M prior year); FY2022 net loss $24.2M ($29.1M prior year).
- Cash at Dec 31, 2022 $3.1M, down from $12.3M year ago; raised $3M post-year-end at $0.84/share.
- R&D expenses Q4 $6.4M (up from $2.2M prior year); FY $19.8M (up from $4.7M prior year) due to clinical trials.
- Clinical progress: PF614 oral HAP study database locked Feb 2023; FDA guidance supports acute pain indication; PF614-MPAR Phase 1 fully enrolled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315223009856/0001493152-23-009856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315223009856/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-009856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer